Treatment of metastatic colorectal cancer in the elderly

Current Treatment Options in Oncology

Volumn 10, Issue 5-6, 2009, Pages 287-295

  Nguyen, Hong L ^a   Hwang, Jimmy ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ACNE; AGE; ANTIANGIOGENIC ACTIVITY; ARTERY THROMBOSIS; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LEUKOPENIA; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; WOUND HEALING IMPAIRMENT;

ADENOCARCINOMA; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; COMORBIDITY; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; ORGANOPLATINUM COMPOUNDS;

EID: 77951025860     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-009-0111-7     Document Type: Review

References (35)

1. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009.
2. Jemal, A.: CA: A Cancer Journal for Clinicians, May 27, 2009; advance online edition. News release, American Cancer Society. American Cancer Society: Cancer Prevention & Early Detection Facts & Figures, 2009.
3. Lichtman, S, et al.: Colorectal Cancer in the Elderly Patient: Assessment and Treatment. New York, NY: Oncology Publishing Group, 2005.
4. McKibbin T, et al.: Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting. Oncologist 2008, 13(8):876-885.
5. Goodwin J, et al.: Determinants of cancer therapy in elderly patients. Cancer 2006, 72(2):594-601.
6. Aapro MS: Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist 2005, 10(3):198-204.
7. Papamichael D: Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol 2009, 20(1):5-16.
8. Baker SD: Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002, 94(24):1883-1888.
9. Honecker F, Kohne CH, Bokemeyer C: Colorectal cancer in the elderly: is palliative chemotherapy of value. Drugs Aging 2003, 20:1-11. (Pubitemid 36127030)
10. Au HJ, Mulder KE, Fields AL: Systemic review of management of colorectal cancer in elderly patients. Clin Colorectal Cancer 2003, 3(3):165-171.
11. Sargent DJ, et al.: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001, 345(15):1091-1097.
12. Feliu J: XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006, 94:969-975.
13. Mattioli R, et al.: High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/ leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol 2005, 16:1147-1151. (Pubitemid 41418318)
14. Figer A, et al.: FOLFOX in Pts aged between 76 and 80 yrs with metastatic colorectal cancer, an exploratory cohort of the OPTIMOX1 Study. Cancer 2007, 110:2666-2671. (Pubitemid 350250335)
15. Goldberg RM, et al.: A pooled analysis to assess safety and efficacy of FOLFOX4 regimen (bimonthly oxaliplatin plus 5FfU/leukovorin) in elderly pts with colorectal cancer. J Clin Oncol 2006, 24:4085-4091.
16. Comella P, et al.: Cepecitabine plus oxaliplatin for the first-line treatment of elderly pts with metstatic CRC. Cancer 2005, 104:282-289.
17. Chau I, et al.: Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer 2004, 91:1453-1458.
18. Fuchs CS, et al.: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003, 21:807-814.
19. Sargent DJ, et al.: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001, 345(2):144-145.
20. Souglakos J, et al.: Combination of irinotecan (CPT- 11) plus 5-fluorouracil and leucovorin (FOLFIRI Regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. Oncology 2005, 69:384-390. (Pubitemid 41797914)
21. Sastre J, et al.: Irinotecan in combination with 5FU in a 48 hr continuous infusion as 1st line for elderly with metastatic colorectal cancer. J Clin Oncol 2005, 23:3534-3551.
22. Folprecht G, Seymour MT, Saltz L, et al.: Irinotecan/ fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 2008, 26(9):1443-1451.
23. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotean, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335-2342.
24. Patt YZ, et al.: Capecitabine plus 3-weekly irinotecan (XELIRI Regimen) as first-line chemotherapy for metastatic colorectal cancer: Phase II trial results. Am J Clin Oncol 2007, 30(4):350-357.
25. Giantonio BJ, et al.: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25(12):1539-1544.
26. Scappaticci FA, et al.: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007, 99(16):1232-1239.
27. Raman AK, et al.: Bevacizumab related adverse events among various age groups of elderly patients with advanced colorectal cancer. J Clin Oncol 2007, 25(18S):14546.
28. Tabernero J, et al.: Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007, 25(33):5225-5232.
29. Lichtman, S., et al.: Chemotherapy Toxicity: Focus on the Older Cancer Patient. New York, NY: Oncology Publishing Group, 2008.
30. Pasetto LM, et al.: How many colorectal cancer (CRC) patients older than 70 years may be safely treated with bevacizumab? J Clin Oncol 2006, 24:13589.
31. Saltz LB, et al.: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26(12):2013-2019.
32. Kabbinavar FF, et al.: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005, 23(16):3697-3705.
33. Cunningham D, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351(4):337-345.
34. Thomas M: Cetuximab: adverse event profile and recommendations for toxicity management. Clin J Oncol Nursing 2005, 9(3):1092-1095.
35. B̈ouchahda MT, et al.: Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit Rev Oncol/Hematol 2008, 67(3):255-262.